Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
IPO Year: 2021
Exchange: NASDAQ
Website: journeymedicalcorp.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/22/2024 | $9.00 | Buy | Rodman & Renshaw |
| 6/28/2024 | $11.00 | Buy | ROTH MKM |
| 2/25/2022 | $9.00 | Overweight | Cantor Fitzgerald |
| 12/16/2021 | $15.00 | Buy | Roth Capital |
| 12/7/2021 | $14.00 | Buy | B. Riley Securities |
10-Q - Journey Medical Corp (0001867066) (Filer)
8-K - Journey Medical Corp (0001867066) (Filer)
8-K - Journey Medical Corp (0001867066) (Filer)
8-K - Journey Medical Corp (0001867066) (Filer)
S-8 - Journey Medical Corp (0001867066) (Filer)
8-K - Journey Medical Corp (0001867066) (Filer)
8-K - Journey Medical Corp (0001867066) (Filer)
10-Q - Journey Medical Corp (0001867066) (Filer)
8-K - Journey Medical Corp (0001867066) (Filer)
8-K - Journey Medical Corp (0001867066) (Filer)
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally advanced cutaneous squamous cell carcinoma MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2024. Lindsay A. Rosenwald, M.D., Fortress' Chairman,
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025 Total revenues for the third quarter ended September 30, 2024 were $14.6 million SCOTTSDALE, Ariz., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results a
SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's Laboratories Ltd. Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Jo
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy Subjects With its modified-release formulation, DFD-29 (40 mg) provides higher dermal concentration than doxycycline from Day 1 onward at a similar dose, expected to translate into a clinically meaningful impact for treating patients with rosacea New Drug Application for DFD-29 under review by FDA with PDUFA goal date of November 4, 2024 SCOTTSDALE, Ariz., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results
SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical's management team will attend one-on-one meetings at the 3rd Annual ROTH Healthcare Opportunities Conference, scheduled to take place on Wednesday, October 9, 2024 in New York City. About Journey Medical CorporationJourney Medical Corporation (NASDAQ:DERM) ("Journey Medical") is a c
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will attend one-on-one meetings at the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference, scheduled to take place on Thursday, September 12, 2024 in New York City. About Journey Medical CorporationJourney Medical Corporation (NASD
SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET. The Company will also atten
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of December 28, 2024 MIAMI, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the second quarter ended J
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million reported in the first quarter of 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for
SC 13G/A - Journey Medical Corp (0001867066) (Subject)
SC 13G - Journey Medical Corp (0001867066) (Subject)
SC 13G - Journey Medical Corp (0001867066) (Subject)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
3 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
3 - Journey Medical Corp (0001867066) (Issuer)
Rodman & Renshaw initiated coverage of Journey Medical with a rating of Buy and set a new price target of $9.00
ROTH MKM resumed coverage of Journey Medical with a rating of Buy and set a new price target of $11.00
Cantor Fitzgerald initiated coverage of Journey Medical with a rating of Overweight and set a new price target of $9.00
Roth Capital initiated coverage of Journey Medical with a rating of Buy and set a new price target of $15.00
B. Riley Securities initiated coverage of Journey Medical with a rating of Buy and set a new price target of $14.00
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's Laboratories Ltd. Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Jo
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million reported in the first quarter of 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for
SCOTTSDALE, Ariz., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2024 financial results after the U.S. financial markets close on Monday, August 12, 2024. Journey Medical management will conduct a conference call and audio webcast on Monday, August 12, 2024 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic)
DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of 2023 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., May 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical pr
SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2024 financial results after the U.S. financial markets close on Monday, May 13, 2024. Journey Medical management will conduct a conference call and audio webcast on Monday, May 13, 2024 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-3
Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings in 2023, ahead of initial guidance of $12.0 million New Drug Application for rosacea treatment candidate DFD-29 accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical co
SCOTTSDALE, Ariz., March 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2023 financial results after the U.S. financial markets close on Thursday, March 21, 2024. Journey Medical management will conduct a conference call and audio webcast on Thursday, March 21, 2024 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-
Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023 GAAP net income increased to $16.8 million, or $0.91 per share basic and $0.80 per share diluted, for the third quarter of 2023, compared to a GAAP net loss of $10.1 million, or $0.57 per share basic and diluted for the third quarter of 2022 Received an upfront payment of $19.0 million upon entering into an exclusive license agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and other Asian nations New Drug Application for DFD-29 expected to be submitted to FDA around the end of 2023 Company to hold conference call today at 4:30 p.m
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company's Interim Chief Financial Officer since January 2023 and he served as the Company's Corporate Controller prior to that since November 2021. Claude Maraoui, Co-Founder, President and Chief
REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced the appointment of Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of Jasper's Board of Directors (the Board), effective immediately. Bill Lis is stepping down as Chairperson and will re
SCOTTSDALE, Ariz., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Ernest (Ernie) De Paolantonio has notified the Company that, effective January 27, 2023, he will step down as Chief Financial Officer of Journey Medical to pursue another opportunity. The Company also today announced the appointment of Joseph M. Benesch as Interim Chief Financial Officer, effective January 27, 2023. Claude Maraoui, Co-Founder, President and Chief E
JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones: The U.S. Food and Drug Administration (FDA) has granted Entera's request for a Type C Meeting based on the revised phase 3 registrational study for lead clinical asset, EB613 (oral formulation of PTH (1-34, teriparatide), as the first oral anabolic drug to treat post-menopausal women with osteoporosis. The meeting is expected in H2 2022Following its End of Phase 2 Meeting with the FDA, Entera designed the pivotal study for EB613 as an 18 month double blind placebo-contro
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera's existing board members, as Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy, effective immediately. "Miranda is an accomplished leader in the biotechnology industry with almost 25 years of C-level leadership, principal investment and capital markets experience," commented Spiros Jamas, Chief Executive Officer of Entera Bio. "Ms. Toledano, as a member of our Board of Directors since 2018, has an extensive understanding of Entera's
Roth MKM analyst Jason Wittes reinstates Journey Medical (NASDAQ:DERM) with a Buy and announces $11 price target.
Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and has discontinued the program. Skye Bioscience shares tumbled 18.9% to $8.87 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Big Tree Cloud Holdings Limited (NASDAQ:DSY) shares jumped 123% to $4.3001 following the completion of the company’s business combination with Plutonian Acquisition Corp. and amid continued volatility following its Nasdaq debut last week. KWESST Micro Systems Inc. (NASDAQ:KWE) gained 79.8% to $0.7082 after the company was aw
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.23) by 130.43 percent. The company reported quarterly sales of $13.000 million which missed the analyst consensus estimate of $14.098 million by 7.79 percent. This is a 6.44 percent increase over sales of $12.213 million the same period last year.
Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company's Interim Chief Financial Officer since January 2023 and he served as the Company's Corporate Controller prior to that since November 2021. Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical, said, "Joe has b
The Dow Jones index closed higher by over 475 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Retractable Technologies The Trade: Retractable Technologies, Inc. (NYSE:RVP) President and CEO Thomas J Shaw acquired a total of 5,096 shares an average price of $1.18. To acquire these shares, it cost around $6,024. What’s Happening: On Nov.
Shares of Westport Fuel Systems Inc. (NASDAQ:WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share. Westport Fuel Systems shares dipped 9.9% to $6.52 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Stoke Therapeutics, Inc. (NASDAQ:STOK) shares gained 72.6% to $11.24 after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. C3is Inc. (NASDAQ:CISS) climbed 65% to $0.0581 after the company reported a year-over-year increase in fourth-q
Gainers Stoke Therapeutics (NASDAQ:STOK) stock moved upwards by 71.8% to $11.16 during Tuesday's regular session. The company's market cap stands at $498.5 million. The company's, Q4 earnings came out yesterday. Mesoblast (NASDAQ:MESO) stock moved upwards by 64.95% to $3.63. The market value of their outstanding shares is at $368.2 million. OpGen (NASDAQ:OPGN) shares increased by 42.1% to $0.68. The company's market cap stands at $6.7 million. Alpha Teknova (NASDAQ:TKNO) shares rose 36.92% to $3.3. The market value of their outstanding shares is at $134.6 million. Nuvation Bio (NYSE:NUVB) shares moved upwards by 32.22% to $2.98. The company's market cap stands at $651.6 million. Journe
Journey Medical (NASDAQ:DERM) reported its Q4 earnings results on Thursday, March 21, 2024 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Journey Medical beat estimated earnings by 138.0%, reporting an EPS of $0.03 versus an estimate of $-0.08. Revenue was down $709 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $1.14 which was followed by a 10.0% increase in the share price the next day. Here's a look at Journey Medical's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.15 -0.33 -0.45 -0.47 EPS Actual 0.99 -0.04 -0.30 -0.17 Revenue Estimate 16.88M 14.81M 16.18M 1
Journey Medical (NASDAQ:DERM) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.08) by 137.5 percent. The company reported quarterly sales of $15.257 million which beat the analyst consensus estimate of $15.061 million by 1.30 percent. This is a 4.44 percent decrease over sales of $15.966 million the same period last year.